AQEMIA
The AI engine Fit Assessment
BetaAqemia effectively utilizes machine learning and quantum algorithms to discover new drug candidates, significantly optimizing the drug discovery process.
Blurb
Aqemia accelerates drug discovery using quantum physics and AI, generating novel drug candidates without experimental data.
HQ Location
Paris (France)
Founded
2019
Employees
51 - 200
Total funding raised
$109.50M
Last Funding Event
Grant, $7.40M, April 1, 2025
Smart insights
- Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
- Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
- 6m headcount growth: 25%
- 1Y headcount growth: 94%
- Headcount-to-last-round ratio: 5.3 employees/$M
Subspaces
- Drug Discovery Optimization
AQEMIA is a pharmatech company developing a drug discovery platform to discover new drugs for specific therapeutic targets. Its platform combines quantum-inspired physics and machine learning to scale the drug discovery process, generating a growing pipeline of new drug candidates. The company utilizes advanced techniques, including generative AI and atomic scale physics, to design novel drugs tailored for specific therapeutic targets.